An antibody for treating advanced prostate cancer improves progression-free survival in patients with metastasized, castration-resistant prostate cancer. This is the finding of the long-term analyses of an international phase 3 clinical trial. The study showed that overall survival was 2 - 3 times higher than in the placebo arm.
from Health & Medicine News -- ScienceDaily https://www.sciencedaily.com/releases/2020/09/200929123451.htm
No comments:
Post a Comment